This company listing is no longer active
N4CN Stock Overview
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Paratek Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$2.02 |
52 Week High | US$3.65 |
52 Week Low | US$1.19 |
Beta | 1.7 |
1 Month Change | 2.90% |
3 Month Change | n/a |
1 Year Change | -13.95% |
3 Year Change | -57.52% |
5 Year Change | -75.32% |
Change since IPO | -86.37% |
Recent News & Updates
Recent updates
Shareholder Returns
N4CN | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | 0.4% | -0.2% | 0.4% |
1Y | -13.9% | -25.2% | 6.7% |
Return vs Industry: N4CN underperformed the German Pharmaceuticals industry which returned -3.5% over the past year.
Return vs Market: N4CN underperformed the German Market which returned 14.4% over the past year.
Price Volatility
N4CN volatility | |
---|---|
N4CN Average Weekly Movement | 5.7% |
Pharmaceuticals Industry Average Movement | 6.2% |
Market Average Movement | 4.7% |
10% most volatile stocks in DE Market | 10.3% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: N4CN has not had significant price volatility in the past 3 months.
Volatility Over Time: N4CN's weekly volatility has decreased from 15% to 6% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1996 | 269 | Evan Loh | https://www.paratekpharma.com |
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd.
Paratek Pharmaceuticals, Inc. Fundamentals Summary
N4CN fundamental statistics | |
---|---|
Market cap | €119.98m |
Earnings (TTM) | -€58.88m |
Revenue (TTM) | €166.13m |
0.7x
P/S Ratio-2.0x
P/E RatioIs N4CN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
N4CN income statement (TTM) | |
---|---|
Revenue | US$177.00m |
Cost of Revenue | US$64.13m |
Gross Profit | US$112.87m |
Other Expenses | US$175.60m |
Earnings | -US$62.73m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.09 |
Gross Margin | 63.77% |
Net Profit Margin | -35.44% |
Debt/Equity Ratio | -128.3% |
How did N4CN perform over the long term?
See historical performance and comparison